/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ziv-aflibercept for DME provides BCVA gains, lower dosing burden


    “Based on our results, ziv-aflibercept seems to be a potential and cost-effective substitute for aflibercept in the same way that bevacizumab is a cost-effective substitute for ranibizumab,” Dr. Soheilian said. “Since vision improvement is the surrogate endpoint and because it is presumably safer to use a lower dose, we suggest using ziv-aflibercept 1.25 mg for treatment of DME.”

    Ziv-aflibercept has the same molecular structure as aflibercept and acts by the same mechanism as a soluble decoy receptor, neutralizing all VEGF-A isoforms. In their commercially available formulations, the two products differ in osmolality, with the value being much higher for ziv-aflibercept compared with aflibercept—820 versus 250 mOsm.

    “It has been shown that the higher osmolality of ziv-aflibercept may have a more damaging effect on the retina and cause retinal detachment,” Dr. Soheilian said. “However, we did not observe any such complications in our study.”

    Other recent studies also show intravitreal ziv-aflibercept is safe and effective treatment without causing ocular toxicity in eyes with retinal disease, Dr. Soheilian noted.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results